Vitamin K Antagonists and Risk of Subdural Hematoma
Clinical Trials Monday, June 9th, 2014STROKEAHA: May 13, 2014
Background and Purpose—Subdural hematomas are an important bleeding complication of anticoagulation. We quantify the risk of subdural hematoma associated with anticoagulation with vitamin K antagonists (VKAs) compared with other oral antithrombotic therapies.
Methods—Randomized trials were identified from the Cochrane Central Register of Controlled Trials and were included if published since 1980 and compared oral VKAs with antiplatelet therapy or with direct-acting oral anticoagulants. Two reviewers independently extracted data with differences resolved by joint review. Read more
